Measuring Pelvic Floor Muscle Fitness Before and After Treatment
a study on Myofacial Pain Pain
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedstudy ends around
- Principal Investigator
- by A Lenore Ackerman, MD, PhD (ucla)
Description
Summary
This study is being done to better understand and improve treatment for myofascial pelvic pain, a common cause of long-lasting pelvic pain in women. Myofascial pelvic pain is related to tight or dysfunctional pelvic floor muscles and can cause pain as well as bladder, bowel, and sexual problems. Current clinical evaluations mostly rely on physical examination and patient-reported symptoms and do not fully measure how the pelvic floor muscles are functioning.
The purpose of this study is to measure pelvic floor muscle function using a noninvasive imaging method called near-infrared spectroscopy, or NIRS. This method measures changes in muscle blood flow and oxygen levels during muscle contraction and relaxation. The study will examine whether pelvic floor muscle function improves after different treatments and whether these physiologic changes are associated with improvements in pain and symptoms.
The study will enroll 120 adult women who have had pelvic pain for at least three months and have pelvic floor muscle tenderness on examination. Participants will be randomly assigned to one of three groups: education with relaxation exercises, pelvic floor physical therapy focused on myofascial release, or vaginal medication used to help relax pelvic floor muscles.
Participants will take part in four study visits over a six-month period. During these visits, they will complete questionnaires about pain and pelvic symptoms, undergo pelvic floor examinations, and have pelvic floor muscle imaging using the NIRS device while performing brief muscle contractions and relaxations. Some visits will also include collection of blood, urine, and vaginal samples to measure inflammation.
The information gained from this study may help improve the diagnosis and treatment of myofascial pelvic pain by providing objective measures of pelvic floor muscle function and identifying which treatments are most effective for different patients.
Official Title
Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain Before and After Myofascially-Directed Therapies
Details
STUDY OVERVIEW This is a prospective, randomized, controlled clinical study designed to objectively measure pelvic floor muscle (PFM) physiology and inflammatory changes in women with myofascial pelvic pain (MPP). The study uses a novel, transvaginal near-infrared spectroscopy (NIRS) system to assess pelvic floor muscle oxygenation, hemodynamics, and recovery during standardized contraction and relaxation tasks. The overarching goal is to improve objective diagnosis, phenotyping, and personalized treatment of MPP.
Scientific Rationale Myofascial pelvic pain is a common contributor to chronic pelvic pain in women and is characterized by pelvic floor muscle hypertonicity, impaired muscle perfusion, local acidosis, and accumulation of inflammatory mediators. These physiologic abnormalities contribute to pain as well as bladder, bowel, and sexual dysfunction. Current clinical evaluation relies largely on subjective examination and patient-reported symptoms, which limits precision in diagnosis and treatment selection.
Preliminary work has demonstrated that pelvic floor NIRS imaging can reliably distinguish women with MPP from asymptomatic controls and can identify physiologic impairments such as reduced muscle oxygenation and delayed recovery following contraction. This study evaluates whether targeted myofascial therapies improve these objective physiologic measures and whether changes in muscle physiology correlate with symptom improvement and inflammatory biomarkers.
STUDY OBJECTIVES
Primary Objective To determine whether pelvic floor muscle fitness, measured using NIRS-derived oxygenation parameters, improves following myofascial-directed treatments in women with MPP.
Secondary Objectives To characterize NIRS-derived physiologic patterns associated with symptom severity and pelvic floor dysfunction.
To assess relationships between NIRS measures and systemic and local inflammatory biomarkers.
To identify physiologic predictors of treatment response using machine-learning-based analytic approaches.
STUDY DESIGN
Design: Prospective, randomized, controlled trial
Sample size: 120 adult women with myofascial pelvic pain
Randomization: 1:1:1 allocation
Treatment arms:
Education and generalized relaxation (control) Myofascially-directed pelvic floor physical therapy Pharmacologic pelvic floor muscle relaxation
Study duration: Six months per participant
Study visits: Baseline, 1-2 weeks, 3 months, and 6 months
Total participant time: Approximately four hours across all visits
STUDY PROCEDURES
Baseline Visit After informed consent, participants complete validated questionnaires assessing pelvic pain, urinary, bowel, sexual function, psychological symptoms, and quality of life. Participants also complete two 24-hour bladder and bowel diaries.
Clinical assessments include urinalysis and post-void residual if not recently documented, standardized pelvic examination with grading of muscle strength and myofascial tenderness, perineometry, surface electromyography, and bulbospongiosus reflex testing. Pelvic floor NIRS imaging is performed transvaginally during a guided 10-minute protocol involving repeated contraction and relaxation exercises, capturing real-time oxygenated and deoxygenated hemoglobin data across multiple circumferential channels.
Biologic specimens, including blood, urine, and vaginal samples, are collected for inflammatory biomarker analysis.
Follow-Up Assessments Participants return at 1-2 weeks, 3 months, and 6 months to repeat symptom questionnaires, bladder and bowel diaries, pelvic floor examination, and NIRS imaging. Participants also complete a patient global impression of improvement assessment at all visits after treatment. Biologic specimen collection is repeated at the early post-treatment visit.
DATA MANAGEMENT AND SAFETY
All study data are collected and managed using secure, HIPAA-compliant electronic data capture systems. Data are de-identified at the time of entry. An independent monitoring process oversees recruitment, protocol adherence, and adverse events. All study procedures are considered minimal risk and consistent with standard gynecologic and pelvic floor physical therapy care.
Keywords
Myofacial Pain, Pelvic Pain, Myofascial Pelvic Pain, Chronic Pelvic Pain, pelvic floor muscle dysfunction, pelvic floor myalgia, pelvic floor hypertonicity, Near-infrared spectroscopy, NIRS imaging, Pelvic floor muscle oxygenation, Pelvic floor muscle blood flow, Pelvic floor muscle fitness, Pelvic floor physical therapy, Myofascial release therapy, Pelvic floor relaxation therapy, Intravaginal diazepam, Intravaginal baclofen, Pelvic floor muscle relaxation medication, Women's pelvic pain, Noninvasive pelvic floor assessment, Pelvic floor imaging, Facial Pain, Vaginismus, Near Infrared Imaging, Pharmacological Release
Eligibility
You can join if…
Open to females ages 18 years and up
Women over 18 years of age
Pelvic Pain for more than 3 months
Report an average daily pain intensity score of at least 4 on a 0 to 10 scale
Palpable trigger/tender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam
Willing to refrain from new clinical treatment that may affect pain during the study period
You CAN'T join if...
Inability to participate in clinic visits
Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®) in the past 6 months
Active UTI or vaginal infection
Pregnancy or childbirth in the past 12 months, currently planning a pregnancy
Illicit Drug addiction/regular use of controlled substances (including marijuana use in the past 2 weeks or during the study period)
Pelvic floor physical therapy in the past 3 months
Malignancy or other serious medical condition (e.g., poorly controlled diabetes [HgA1c > 8], chronic renal disease [GFR <30], neurologic or rheumatic disease)
Diagnosed with an alternate cause of pelvic pain (e.g., ulcerative interstitial cystitis, vestibulodynia, vulvar dermatoses, dysmenorrhea)
Urinary retention with a PVR >150 mL
Greater than stage 3 pelvic organ prolapse
Indwelling vaginal devices (e.g., pessary, contraceptive ring. Not including Mirena IUD) that cannot be removed for the study
Inability to sign an informed consent, fill out questionnaires, or complete study interviews
Location
- UCLA
Los Angeles California 90095 United States
Lead Scientist at University of California Health
- A Lenore Ackerman, MD, PhD (ucla)
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- University of California, Los Angeles
- ID
- NCT07605598
- Study Type
- Interventional
- Participants
- Expecting 120 study participants
- Last Updated